Immunomodulatory Effect of MSCs and MSCs-Derived Extracellular Vesicles in Systemic Lupus Erythematosus

Yang, Chunjuan; Sun, Junqiang; Yi-peng, Tian; Li, Haibo; Zhang, Lili; Yang, Jinghan; Wang, Jinghua; Zhang, Jiaojiao; Yan, Shushan; Xu, Dongmei

doi:10.3389/fimmu.2021.714832

Cited by 21 publications

(15 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the above experiments, the rhCol III-EVs hydrogel could better regulate macrophages to transform into the anti-inflammatory phenotype. Multiple studies have shown that MSC-EVs are less immunogenic and inhibit the development and progression of experimental diabetes in animal models by modulating the M1/M2 balance [ 41 ]. MSC-EVs express several adhesion molecules (CD29, CD44 and CD73) that allow them to home to injured and inflamed tissues.…”

Section: Discussionmentioning

confidence: 99%

Preparation of Recombinant Human Collagen III Protein Hydrogels with Sustained Release of Extracellular Vesicles for Skin Wound Healing

Liu

Tang

et al. 2022

IJMS

View full text Add to dashboard Cite

Existing treatment methods encounter difficulties in effectively promoting skin wound healing, making this a serious challenge for clinical treatment. Extracellular vesicles (EVs) secreted by stem cells have been proven to contribute to the regeneration and repair of wound tissue, but they cannot be targeted and sustained, which seriously limits their current therapeutic potential. The recombinant human collagen III protein (rhCol III) has the advantages of good water solubility, an absence of hidden viral dangers, a low rejection rate and a stable production process. In order to achieve a site-specific sustained release of EVs, we prepared a rhCol III hydrogel by cross-linking with transglutaminase (TGase) from Streptomyces mobaraensis, which has a uniform pore size and good biocompatibility. The release profile of the rhCol III-EVs hydrogel confirmed that the rhCol III hydrogel could slowly release EVs into the external environment. Herein, the rhCol III-EVs hydrogel effectively promoted macrophage changing from type M1 to type M2, the migration ability of L929 cells and the angiogenesis of human umbilical vein endothelial cells (HUVECs). Furthermore, the rhCol III-EVs hydrogel is shown to promote wound healing by inhibiting the inflammatory response and promoting cell proliferation and angiogenesis in a diabetic rat skin injury model. The reported results indicate that the rhCol III-EVs hydrogel could be used as a new biological material for EV delivery, and has a significant application value in skin wound healing.

show abstract

Section: Discussionmentioning

confidence: 99%

Preparation of Recombinant Human Collagen III Protein Hydrogels with Sustained Release of Extracellular Vesicles for Skin Wound Healing

Liu

Tang

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Besides, MSC-Exos can inhibit the formation of Th17 and plasmablasts and promote the formation of Treg cells in CIA mice (4). In SLE, MSC-Exos can deliver miR-155-5p, miR-10a, miR-142-3p and miR-216a-5p to produce antiinflammatory immunosuppressive effects on immune cells such as B cells and T cells (81). Riazifar et al (82) found that MSC-Exos contained several mRNAs (such as indoleamine 2,3dioxygenase, thymosin beta 10 pseudogene 1, etc.)…”

Section: Msc-exosmentioning

confidence: 99%

Knowledge Mapping of Exosomes in Autoimmune Diseases: A Bibliometric Analysis (2002–2021)

Gao²,

Kang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAutoimmune diseases (AIDs) are a class of chronic disabling diseases characterized by inflammation and damage to muscles, joints, bones, and internal organs. Recent studies have shown that much progress has been made in the research of exosomes in AIDs. However, there is no bibliometric analysis in this research field. This study aims to provide a comprehensive overview of the knowledge structure and research hotspots of exosomes in AIDs through bibliometrics.MethodPublications related to exosomes in AIDs from 2002 to 2021 were searched on the web of science core collection (WoSCC) database. VOSviewers, CiteSpace and R package “bibliometrix” were used to conduct this bibliometric analysis.Results312 articles from 48 countries led by China and the United States were included. The number of publications related to exosomes in AIDs is increasing year by year. Central South University, Sun Yat Sen University, Tianjin Medical University and University of Pennsylvania are the main research institutions. Frontiers in immunology is the most popular journal in this field, and Journal of Immunology is the most co-cited journal. These publications come from 473 authors among which Ilias Alevizos, Qianjin Lu, Wei Wei, Jim Xiang and Ming Zhao had published the most papers and Clotilde Théry was co-cited most often. Studying the mechanism of endogenous exosomes in the occurrence and development of AIDs and the therapeutic strategy of exogenous exosomes in AIDs are the main topics in this research field. “Mesenchymal stem cells”, “microRNA”, “biomarkers”, “immunomodulation”, and “therapy” are the primary keywords of emerging research hotspots.ConclusionThis is the first bibliometric study that comprehensively summarizes the research trends and developments of exosomes in AIDs. This information identifies recent research frontiers and hot directions, which will provide a reference for scholars studying exosomes.

show abstract

“…Non-HSC bone marrow stromal cells exhibit self-renewal and multipotency into various mesenchymal cell lineages, such as osteoblasts, adipocytes, and chondrocytes; the term MSCs was proposed and remains the most frequently used term [ 5 ]. MSCs have been found in various mesenchymal tissues and organs, such as the adipose tissue, liver, muscle, and umbilical cord [ 6 ]. Recently, the International Society for Cellular Therapy (ISCT) proposed the following minimum criteria for characterizing MSCs [ 7 ]: MSCs (1) exhibit adherence on a plastic culture dish/flask; (2) are positive for CD105, CD90, and CD73, but negative for CD34, CD45, CD14, CD11b, CD79 alpha, or CD19, and human leukocyte antigen DR (HLA-DR); and (3) show multi-differentiation capacity into osteoblasts, adipocytes, and chondrocytes in vitro.…”

Section: Characterization Of Hdpscsmentioning

confidence: 99%

A New Target of Dental Pulp-Derived Stem Cell-Based Therapy on Recipient Bone Marrow Niche in Systemic Lupus Erythematosus

Sonoda

Yamaza

2022

IJMS

View full text Add to dashboard Cite

Recent advances in mesenchymal stem/stromal cell (MSC) research have led us to consider the feasibility of MSC-based therapy for various diseases. Human dental pulp-derived MSCs (hDPSCs) have been identified in the dental pulp tissue of deciduous and permanent teeth, and they exhibit properties with self-renewal and in vitro multipotency. Interestingly, hDPSCs exhibit superior immunosuppressive functions toward immune cells, especially T lymphocytes, both in vitro and in vivo. Recently, hDPSCs have been shown to have potent immunomodulatory functions in treating systemic lupus erythematosus (SLE) in the SLE MRL/lpr mouse model. However, the mechanisms underlying the immunosuppressive efficacy of hDPSCs remain unknown. This review aims to introduce a new target of hDPSC-based therapy on the recipient niche function in SLE.

show abstract

Immunomodulatory Effect of MSCs and MSCs-Derived Extracellular Vesicles in Systemic Lupus Erythematosus

Cited by 21 publications

References 146 publications

Preparation of Recombinant Human Collagen III Protein Hydrogels with Sustained Release of Extracellular Vesicles for Skin Wound Healing

Preparation of Recombinant Human Collagen III Protein Hydrogels with Sustained Release of Extracellular Vesicles for Skin Wound Healing

Knowledge Mapping of Exosomes in Autoimmune Diseases: A Bibliometric Analysis (2002–2021)

A New Target of Dental Pulp-Derived Stem Cell-Based Therapy on Recipient Bone Marrow Niche in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About